Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.41 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.40 |
| ▸ | FUT6 | P51993 | 1/20 | 0.40 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.40 |
| ▸ | ST3GAL1 | Q11201 | 1/20 | 0.40 |
| ▸ | ST3GAL3 | Q11203 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SQLE | Q14534 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075081 | 0.90 | ALOX5 (0.44) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL16406504 | 0.90 | ALOX5 (0.44) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL16406480 | 0.90 | ALOX5 (0.44) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL16406484 | 0.84 | ALOX5 (0.44) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL16406486 | 0.84 | DHODH (0.45) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL16406483 | 0.83 | ALOX5 (0.41) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 | |
| SCHEMBL30645386 | 0.81 | ALOX5 (0.45) | ALOX5MAOB | |
| SCHEMBL16406492 | 0.79 | APP (0.44) | ALOX5MAOB | |
| SCHEMBL16406491 | 0.79 | ALOX5 (0.42) | ALOX5MAOB | |
| SCHEMBL21972848 | 0.76 | ALOX5 (0.39) | ALOX5ST6GAL1FUT6FUT5ST3GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216987-B2 | Chroman derivative | TMS CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216987-B2 | Chroman derivative | TMS CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20150025251-A1 | CHROMAN DERIVATIVE | TMS CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025251-A1 | CHROMAN DERIVATIVE | TMS CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025251-A1 | CHROMAN DERIVATIVE | CDYL, CNOT1, CNPY2 | ALOX5 3596/4885ST6GAL1 3125/4885FUT6 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.